ZRB1003
Anti-c-Myc Antibody, clone 7E18, ZooMAb® Rabbit Monoclonal
recombinant, expressed in HEK 293 cells
Synonym(s):
Class E basic helix-loop-helix protein 39, Myc proto-oncogene protein, Proto-oncogene c-Myc, Transcription factor p64, bHLHe39
Sign Into View Organizational & Contract Pricing
All Photos(27)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
biological source
rabbit (recombinant)
Quality Level
recombinant
expressed in HEK 293 cells
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
7E18, recombinant monoclonal
monoclonal
product line
ZooMAb® learn more
form
lyophilized
mol wt
calculated mol wt 48.8 kDa
observed mol wt ~55 kDa
species reactivity
mouse, human
packaging
antibody small pack of 25 μL
greener alternative product characteristics
Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
sustainability
Greener Alternative Product
technique(s)
gene knockdown: suitable using 1:1,000
immunocytochemistry: 1:100-1:250
immunohistochemistry: suitable using 1:100
western blot: suitable using 1:1,000
isotype
IgG
UniProt accession no.
greener alternative category
shipped in
ambient
storage temp.
2-8°C
target post-translational modification
unmodified
Gene Information
human ... MYC;BHLHE39(4609)
General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.
Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.
Learn more about ZooMAb here.
Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.
Learn more about ZooMAb here.
Specificity
Clone 7E18 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects human Myc proto-oncogene protein (c-Myc).
Immunogen
GST/His-tagged recombinant fragment corresponding to 109 amino acids from the internal region of human c-Myc.
Application
Anti-c-Myc, clone 7E18, ZooMAb, Cat. No. ZRB1003-25UL, is a recombinant Rabbit Monoclonal Antibody that specifically targets c-Myc proto-oncogene and has been tested for use in Immunocytochemistry, Immunohistochemistry, RNAi/siRNA/Gene Knockdown, and Western Blotting,
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected c-Myc in human kidney, mouse testis, and human cervical cancer tissue sections.
RNAi/siRNA/Gene Knockdown Analysis: A 1:1000 dilution from a representative lot detected c-Myc in lysate from wild-type HEK293 cells, but not in HEK293 cells with c-myc knocked out using CRISPR.
Immunocytochemistry Analysis: A 1:250 dilution from a representative lot detected Myc proto-oncogene protein in HeLa, A431, HUVEC, and NIH 3T3 cell lines.
RNAi/siRNA/Gene Knockdown Analysis: A 1:1000 dilution from a representative lot detected c-Myc in lysate from wild-type HEK293 cells, but not in HEK293 cells with c-myc knocked out using CRISPR.
Immunocytochemistry Analysis: A 1:250 dilution from a representative lot detected Myc proto-oncogene protein in HeLa, A431, HUVEC, and NIH 3T3 cell lines.
Target description
Myc proto-oncogene protein (UniProt: P01106; also known as Class E basic helix-loop-helix protein 39, bHLHe39, Proto-oncogene c-Myc, Transcription factor p64) is encoded by the MYC (also known as BHLHE39) gene (Gene ID: 4609) in human. c-Myc is a transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5′-CAC[GA]TG-3′. It regulates the expression of multiple genes involved in apoptosis, cell differentiation and cell proliferation. c-Myc is shown to be critically involved in the regulation of several growth promoting signaling pathways and is considered as an immediate early response gene that is downstream of many ligand-membrane receptor complexes. Its expression is reported to be tightly regulated by several transcriptional regulatory motifs within its proximal promoter region. Phosphorylation of c-Myc by serine/threonine kinase PIM2 at serine 329 is reported to lead to its stabilization. Active c-Myc is coupled to the MAX protein via its C-terminal helix-loop-helix leucine zipper (bHLHLZ) domain (aa 413-434) and this heterodimer interacts with a number of other transcription-related proteins. In normal cells its expression and function are regulated by developmental or mitogenic signals. c-Myc mRNA has a very short half-life and in the absence of positive regulatory signals there is a significant reduction in its transcription leading to low c-Myc protein levels that does not have any proliferative drive. However, in tumor cells its levels are increased either via mutations or induction via upstream oncogenic pathways. Mutations in c-Myc gene are known to cause B-cell chronic lymphocytic leukemia and Burkitt lymphoma. Over-expression of c-Myc has been reported in about 40% tumors. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Miller, DM et al., (2012). Clin. Cancer Res. 18(20); 5546-5553).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
Reconstitution
300 μg/mL after reconstitution at 25 μL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
11 - Combustible Solids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Svetlana V Demyanenko et al.
Cells, 11(1) (2022-01-12)
The search for effective neuroprotective agents for the treatment of neurotrauma has always been of great interest to researchers around the world. Extracellular heat shock protein 70 (eHsp70) is considered a promising agent to study, as it has been demonstrated
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service